###begin article-title 0
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 1078 1082 <span type="species:ncbi:10090">mice</span>
###xml 1206 1214 <span type="species:ncbi:9606">patients</span>
Platelets play an important role in hemostasis, with inappropriate platelet activation being a major contributor to debilitating and often fatal thrombosis by causing myocardial infarction and stroke. Although current antithrombotic treatment is generally well tolerated and effective, many patients still experience cardiovascular problems, which may reflect the existence of alternative underlying regulatory mechanisms in platelets to those targeted by existing drugs. In this study, we define a role for peripherally distributed members of the tachykinin family of peptides, namely substance P and the newly discovered endokinins A and B that are present in platelets, in the activation of platelet function and thrombus formation. We have reported previously that the preferred pharmacologically characterized receptor for these peptides, the NK1 receptor, is present on platelets. Inhibition or deficiency of the NK1 receptor, or SP agonist activity, resulted in substantially reduced thrombus formation in vitro under arterial flow conditions, increased bleeding time in mice, and a decrease in experimentally induced thromboembolism. Inhibition of the NK1 receptor may therefore provide benefit in patients vulnerable to thrombosis and may offer an alternative therapeutic target.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 181 182 181 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B1">1</xref></sup>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B2">2</xref></sup>
###xml 400 403 396 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIb</sub>
###xml 407 408 400 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 543 544 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 543 544 536 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B3">3</xref></sup>
###xml 689 690 682 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 831 832 824 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 831 832 824 825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B4">4</xref></sup>
Tissue damage results in the local exposure, generation, or release of factors such as collagen and thrombin that trigger the function of platelets, and thereby initiate hemostasis.1 Through the function of multiple cell adhesion and signaling receptors, platelets become entrapped at the injury site and become activated.2 This leads ultimately to the up-regulation in affinity of the integrin alphaIIbbeta3 which, through binding ligands that include fibrinogen and von Willebrand factor, support the formation of a stable platelet thrombus.3 Effective thrombus formation in the arterial circulation is dependent on the secretion and release of factors such as ADP and thromboxane (TX) A2 from activated platelets, which through binding G protein-coupled receptors on the platelet surface, stimulate positive feedback activation.4
###end p 4
###begin p 5
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B5">5</xref></sup>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 127 128 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B6">6</xref></sup>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B7">7</xref></sup>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 159 160 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B8">8</xref></sup>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B9">9</xref></sup>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 313 315 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
Roles in thrombus formation have been discovered for a number of newly identified regulatory molecules, including gas6,5 CD40L,6 semaphorin 3A,7 semaphorin 4D,8 and ephrins/eph kinases.9 We recently demonstrated that substance P (SP), a member of the tachykinin family, may also contribute to platelet regulation.10 We showed that SP can stimulate activation and aggregation of platelets and that platelets contain SP immunoreactivity that is released upon activation.
###end p 5
###begin p 6
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 126 128 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref></sup>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 608 608 608 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13"/>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 606 611 606 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B12">12</xref><xref ref-type="bibr" rid="B13"/>&#8211;<xref ref-type="bibr" rid="B14">14</xref></sup>
###xml 888 892 888 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 976 978 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 976 981 976 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B15">15</xref></sup>
###xml 1258 1259 1258 1259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1364 1366 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1367 1369 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1370 1372 1370 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1364 1372 1364 1372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref></sup>
###xml 1374 1381 1374 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1778 1780 1778 1780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1778 1780 1778 1780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref></sup>
###xml 1974 1976 1974 1976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1974 1976 1974 1976 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 985 989 <span type="species:ncbi:10090">mice</span>
###xml 1077 1083 <span type="species:ncbi:9606">humans</span>
###xml 1852 1857 <span type="species:ncbi:9606">human</span>
###xml 1958 1963 <span type="species:ncbi:10090">mouse</span>
Tachykinins are a family of peptides characterized by the conserved C-terminal motif Phe-X-Gly-Leu-Met-NH2 (X is hydrophobic),11 which is central to their biological activity. Originally classified as neurotransmitters, this family of peptides comprising substance P, neurokinin A (NKA), and neurokinin B (NKB) mediates a variety of peripheral biological functions, including smooth muscle contraction, vasodilatation, plasma extravasation, neurogenic inflammation, and hematopoiesis, and there is a growing body of evidence to suggest that they may mediate their actions through endocrine/paracrine modes.12-14 The secretion of NKB by the placenta and the SP-like immunoreactivity released by platelets upon activation (and the observation that synthetic substance P can stimulate aggregation) are 2 such examples. This has been reinforced by the identification of a new tachykinin gene TAC4, which is almost exclusively expressed in peripheral tissues of nonneuronal origin.11,15 In mice, it gives rise to a single transcript containing an NK1 receptor agonist hemokinin; in humans, it encodes 4 transcripts containing endokinins A and B (EKA and EKB) with 2 transcripts (EKC and EKD) containing additional cryptic tachykinin sequences Phe-X-Gly-Leu-Leu-NH2 where X is the hydrophilic amino acid glutamine and thus lack activity at the known tachykinin receptors11,15,16 (Table 1). Unlike SP, NKA, and NKB, hemokinin and endokinins are not conserved throughout mammalian species. Tachykinins are believed to exert their actions via the 3 tachykinin receptors that have been cloned and characterized: NK1, NK2, and NK3, which bind preferentially to SP, NKA, and NKB, respectively, although each of these peptides is able to bind each of the receptors, albeit at lower affinity.11 We have reported previously the expression of NK1 and NK3 receptors on human platelets, and that the level of activation of platelets by SP is reduced in NK1 receptor-deficient mouse platelets.10
###end p 6
###begin p 7
Alignment of the amino acid sequences of the mammalian tachykinins
###end p 7
###begin p 8
###xml 35 40 <span type="species:ncbi:9606">human</span>
HK-1 indicates hemokinin 1; hHK-1, human hemokinin; hHK-1 (4-11), a truncated version of hemokinin 1; and EKA/B, C-terminal sequence shared by endokinins A,B.
###end p 8
###begin p 9
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 84 86 84 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref></sup>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 157 159 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 325 330 <span type="species:ncbi:9606">human</span>
Due to the expression of all 4 TAC4 transcripts in a human megakaryocytic cell line,11 and the inability of immunoassays to distinguish between EKA/B and SP,10 suggesting human platelets as potential peripheral sources of each of these peptides, we have characterized the effects of these peripheral NK1 receptor agonists on human platelet function and demonstrate their prothrombotic potential. We illustrate the importance of the NK1 receptor in thrombogenesis and confirm that disruption of this axis impairs thrombus formation, hemostasis, and thrombosis.
###end p 9
###begin title 10
Methods
###end title 10
###begin title 11
Materials
###end title 11
###begin p 12
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 185 190 185 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref></sup>
###xml 396 399 396 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111</sup>
###xml 626 627 626 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 721 722 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 1303 1305 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1303 1305 1299 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B19">19</xref></sup>
###xml 1518 1520 1514 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1521 1523 1517 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1524 1526 1520 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1518 1526 1514 1522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref></sup>
###xml 13 28 <span type="species:ncbi:10090">transgenic mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
Gq-deficient transgenic mice were provided by F. Lanza (Strasbourg, France) and S. Offermanns (Heidelberg, Germany). NK1- and TAC1-deficient mice were generated as described previously.17,18 All protocols involving the use of animals were approved by University of Reading or Imperial College London Local Ethical Review Panels and covered by Home Office licences. Male Balb/c mice (20/30 g) and 111Indium oxine were purchased from Harlan (Bicester, United Kingdom) and GE Healthcare (Chalfont St Giles, United Kingdom), respectively. Peptides were synthesized by Cambridge Research Biochemicals (Cleveland, United Kingdom), [3H] arachidonic acid was purchased from GE Healthcare, 3,3'-dihexyloxacarbocyanine iodide (DIOC6) was obtained from Sigma-Aldrich (Dorset, United Kingdom), and microcapillaries were supplied by Camlab (Cambridge, United Kingdom). YM254890 and Cangrelor were kindly provided by Astellas (Tokyo, Japan) and The Medicines Company (Parsippany, NJ), respectively. MRS2179 and L733060 were purchased from Sigma (Poole, United Kingdom), and SQ29548 was purchased from Alexis (Axxora, Nottingham, United Kingdom). Anti-P-selectin antibodies (AK-4) were purchased from BD Biosciences (Oxford, United Kingdom). Anti-FcgammaRIIa antibodies (mAbIV.3) were produced as described previously.19 Texas red- and phycoerythrin-conjugated secondary antibodies were purchased from Abcam (Cambridge, United Kingdom) and BD Biosciences, respectively. All other reagents used were from sources described previously.10,20,21
###end p 12
###begin title 13
Peptides
###end title 13
###begin p 14
###xml 20 21 20 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 23 30 23 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
EKA/B (GKASQFFGLM-NH2; Table 1) was synthesized using standard Fmoc methodology. EKA/B and SP were dissolved in acetic acid that was present in functional assays at 0.001% (vol/vol).
###end p 14
###begin title 15
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human platelet aggregation
###end title 15
###begin p 16
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B20">20</xref></sup>
###xml 215 220 <span type="species:ncbi:9606">human</span>
Washed platelets were prepared from fresh blood obtained from aspirin-free donors by differential centrifugation and aggregation measured by optical aggregometry as described previously.20 Informed consent from all human subjects donating blood was obtained, and procedures were approved by the University of Reading Local Ethics Committee.
###end p 16
###begin title 17
Dense granule secretion and arachidonic acid release
###end title 17
###begin p 18
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 132 134 132 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B22">22</xref></sup>
Platelets were loaded with [3H] 5-HT or [3H] arachidonic acid, and release following secretion was measured as described previously.22
###end p 18
###begin title 19
Alpha-granule secretion
###end title 19
###begin p 20
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 172 174 172 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
As a measure of alpha-granule secretion, surface exposure of P-selectin was assessed by flow cytometry using an anti-CD62P (P-selectin) antibody using standard methodology.10
###end p 20
###begin title 21
Immunofluorescence studies
###end title 21
###begin p 22
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B23">23</xref></sup>
###xml 407 408 407 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 26 31 <span type="species:ncbi:9940">sheep</span>
###xml 369 374 <span type="species:ncbi:9606">Human</span>
###xml 643 649 <span type="species:ncbi:9913">bovine</span>
###xml 953 958 <span type="species:ncbi:9940">sheep</span>
Antibodies were raised in sheep to the peptide sequence AETWEGAGPSIQLQEVK, a unique sequence that is not present in SP, which lies upstream of the common C-terminal sequence of both EKA and EKB (precursor residues 30-47).23 Antisera titers were monitored using an enzyme-linked immunosorbent assay (ELISA) and high-titer bleeds selected for immunofluorescence studies. Human platelets were labeled with DIOC6 and applied to glass coverslips using a cytospin3 system (Shandon, Thermo Scientific, High Wycombe, United Kingdom). Platelets were fixed with 2% paraformaldehyde and blocked with modified Tyrode-HEPES buffer containing 0.1% (wt/vol) bovine serum albumin (BSA/Tyrode). Slides were incubated with a 1:100 dilution in BSA/Tyrode of antiserum, preimmune serum, or antiserum to which immunogen peptide (10 mug/mL) had been added 30 minutes prior to use, and incubated for 30 minutes. Slides were washed and incubated with Texas red-conjugated anti-sheep IgG antibody for 20 minutes and examined using a Leica DMIRE2 inverted confocal microscope (x 63 glycerol immersion objective lens; Leica, Milton Keynes, United Kingdom) to visualize platelets (488 nm) and endokinin expression (594 nm).
###end p 22
###begin title 23
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse platelet preparation and aggregation assay
###end title 23
###begin p 24
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 258 260 258 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 29 34 <span type="species:ncbi:10090">mouse</span>
Platelets were isolated from mouse blood and washed, and aggregation assays were performed using levels of single platelets (using a Z2 Coulter Counter; Beckman Coulter, Hialeah, FL) following stimulation as a measure of aggregation, as described previously.10
###end p 24
###begin title 25
Flow microscopy
###end title 25
###begin p 26
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 190 192 189 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 370 371 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 304 319 <span type="species:ncbi:10090">transgenic mice</span>
Whole citrated blood obtained from aspirin-free donors was incubated with fluorescent dye (DIOC6) and perfused through collagen-coated (100 mug/mL) microcapillaries at a sheer rate of 1000 s-1 in the presence of NK1 antagonist L733060 or vehicle control. Alternatively, blood obtained from NK1-deficient transgenic mice or litter-matched controls was incubated with DIOC6 and perfused through collagen-coated capillaries. Tyrode-HEPES buffer was perfused through the microcapillaries to wash out red blood cells, leaving thrombi formed on the immobilized collagen. Thrombi were then visualized using a Leica DMIRE2 inverted confocal microscope (using N PLANL 20x/0.4 objective lens with 0- to 2-mm correction) and thrombus volume calculated from Z-series images captured and analyzed using TCS SP2 software (Leica). To measure protein concentration, 50 muL Tris-buffered saline containing NP40 (1% vol/vol) was perfused through the capillaries, the lysates were collected, and Bradford Protein Assay was performed.
###end p 26
###begin title 27
Tail bleeding assay
###end title 27
###begin p 28
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were anesthetized using ketamine (80 mg/kg) and xylazine (5 mg/kg) administered via the intraperitoneal route, and placed on a heated mat. A total of 1 mm of tail tip was removed using a scalpel blade, and the tail tip was bathed in sterile saline at 37degreesC. The time to cessation of bleeding was measured up to 10 minutes, after which the assay was terminated.
###end p 28
###begin title 29
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse model of thromboembolism
###end title 29
###begin p 30
###xml 162 165 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111</sup>
###xml 293 296 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111</sup>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 286 291 <span type="species:ncbi:10090">mouse</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">Mice</span>
Blood was collected from terminally anesthetized donor mice by cardiac puncture as described and resuspended in modified Tyrode buffer and incubated with 1.8 MBq 111Indium oxine at room temperature for 5 minutes. Platelets were washed and resuspended in 200 muL Tyrode buffer per donor mouse. 111Indium oxine-labeled platelets were infused into the tail vein of the recipient mice and left to equilibrate for 20 minutes. Mice were anesthetized and injected intraperitoneally with vehicle control buffer (Tyrode-HEPES buffer) or the NK1 receptor antagonist L733060 (10 mg/kg) 5 minutes prior to administration of collagen (100 mug/kg) by intravenous injection into the femoral vein. Accumulation of platelets in the pulmonary vasculature was measured as changes in platelet-associated counts using a 1-cm single-point extended area radiation detector (eV Products, Saxonburg, PA) and recorded using custom software (Mumed Systems, London, United Kingdom) on a UCS-20 spectrometer (Spectrum Techniques, Oak Ridge, TN). A detailed description of this model is provided elsewhere (C. Tymvios, S.J., C. Moore, S. C. Pitchford, C. P. Page, M.E., manuscript submitted, July 2007).
###end p 30
###begin p 31
###xml 145 149 <span type="species:ncbi:10090">mice</span>
Data were acquired as percentage change in basal counts and expressed as maximal percentage response where responses for vehicle control treated mice were taken as 100% response plus or minus SEM.
###end p 31
###begin title 32
Statistical analysis
###end title 32
###begin p 33
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Aggregation traces are representative of at least 3 separate experiments from different donors. Numerical data are presented as means plus or minus SEM, and statistical significance was analyzed by t test.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
Peripheral tachykinins stimulate platelet activation
###end title 35
###begin p 36
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 205 207 205 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 327 329 327 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref></sup>
###xml 573 580 573 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 826 828 826 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref></sup>
The potential role of peripheral tachykinins in the regulation of hemostasis was examined using a number of experimental approaches. While the effects of SP on platelets have been previously characterized,10 very little is known of the functional effects of the endokinins. Since TAC4 mRNAs are present in megakaryocytic cells,11 endokinins, in addition to SP, were incorporated into the present study. The processing of EKA/B is incompletely understood, but EKA is predicted to be 47 amino acids in length, and EKB is predicted to be 41 amino acids in length. As shown in Table 1, they share some sequence identity with SP at the C-terminus, which includes the tachykinin consensus motif required for receptor activation. In this study, the common C-terminus sequence of EKA/B, which has been pharmacologically characterized,11 was used.
###end p 36
###begin p 37
###xml 295 303 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 434 439 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Blood</italic>
###xml 527 534 524 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 589 591 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 589 591 586 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref></sup>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Initial experiments confirmed the ability of EKA/B to regulate human platelet function in vitro. EKA/B stimulated maximal aggregation, calculated as a percentage of light transmission through the buffer in which the platelets were suspended, using 5 muM EKA/B, which stimulated 48.4% (+/- 2.5%; Figure 1A). This was comparable with maximum aggregation produced by collagen and SP under similar conditions (Figure S1, available on the Blood website; see the Supplemental Materials link at the top of the online article). EKC/D (Table 1), which do not bind to the known neurokinin receptors,11 were unable to stimulate platelet activation (data not shown).
###end p 37
###begin p 38
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peripheral tachykinins, EKA/B, stimulate functional responses in platelets.</bold>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 364 365 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 381 382 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 602 603 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 613 614 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 625 626 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Peripheral tachykinins, EKA/B, stimulate functional responses in platelets. Washed platelets (A,D) or those loaded with the intracellular calcium chelator BAPTA-AM (B), [3H]5-HT (C), or [3H] arachidonic acid (E) were stimulated with vehicle alone (acetic acid 0.001%) or EKA/B. The results represent percentages of platelet aggregation (A,B), percentage of total [3H]-5HT (C), or [3H] arachidonic acid (E) taken up into the platelet and released, or surface fluorescence of PE-conjugated anti-CD62P antibody as a measure of alpha-granule secretion (D). n = 3 (A-C); n = 4 (E); mean plus or minus SEM. *P < .05; **P < .01; ***P < .001. Panel D is representative of 3 separate experiments.
###end p 38
###begin p 39
###xml 592 600 584 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 853 861 845 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1040 1048 1031 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1113 1114 1104 1105 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1158 1159 1149 1150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1164 1165 1155 1156 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1167 1169 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1167 1169 1158 1160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B24">24</xref></sup>
###xml 1263 1264 1254 1255 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1265 1267 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1268 1270 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1265 1270 1256 1261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B25">25</xref></sup>
###xml 1355 1356 1346 1347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1680 1688 1662 1670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
To ensure that aggregation was not a consequence of peptide-induced agglutination but a result of receptor-mediated platelet activation, EKA/B-mediated activation was measured using platelets loaded with the intracellular calcium chelator BAPTA-AM. Consistent with the involvement of receptor-mediated mobilization of calcium from intracellular stores, BAPTA-AM reduced EKA/B-mediated (5 muM) aggregation in a dose dependent-manner by 15.5% (+/- 1.8%), 55.7% (+/- 3.2%), 72.1% (+/- 2.6%), and 100% compared with the vehicle control, at concentrations of 10, 20, 40, and 80 muM, respectively (Figure 1B). Dense granule secretion was examined using radiolabeled 5-hydroxytryptamine (5-HT). Platelets loaded with radiolabeled 5-HT were stimulated with EKA/B, and secreted radioactivity was measured. 5-HT secretion was observed in a dose-dependent manner (Figure 1C). Similarly, alpha-granule secretion was stimulated by EKA/B in a dose-dependent manner between concentrations of 2.5 and 7.5 muM as assessed by surface exposure of P-selectin (Figure 1D). A number of platelet agonists have been shown to increase TXA2 production by activation of phospholipase A2 (PLA2),24 which liberates arachidonic acid from phospholipid membranes that is converted rapidly to TXA2.23,25 To ascertain whether EKA/B could liberate arachidonic acid and therefore promote TXA2 synthesis, arachidonic acid release was measured from EKA/B-stimulated platelets preloaded with radiolabeled arachidonic acid. Arachidonic acid release from platelets was increased by 0.3% (+/- 0.2%), 0.71% (+/- 0.2%), 1.0% (+/- 0.3%), and 1.1% (+/- 0.3%) at concentrations of, 2.5, 5, 7.5, and 10 muM EKA/B, respectively (Figure 1E).
###end p 39
###begin p 40
###xml 170 171 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 302 303 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 355 356 355 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 453 461 452 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 499 500 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 605 613 595 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 737 738 727 728 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 746 748 736 738 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 763 764 753 754 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 799 801 788 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 912 920 898 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 944 952 928 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
The platelet response observed with agonists such as collagen is often largely dependent on the release of secondary agonists from the platelet, predominantly ADP and TXA2. Similarly responses to EKA/B were dependent on the liberation of arachidonic acid and the subsequent synthesis and release of TXA2. Blocking the conversion of arachidonic acid to TXA2 using the cyclo-oxygenase inhibitor indomethacin (10 muM) abolished EKA/B-mediated aggregation (Figure 2A). Furthermore, antagonism of the TXA2 receptors TPalpha and beta by SQ29548 (20 nM) inhibited EKA/B-mediated aggregation by 84.14% (+/- 6.8%; Figure 2B). Antagonism of the 2 purinergic receptors present on platelets demonstrated the requirement of signaling through both P2Y1 and P2Y12 receptors. P2Y1 antagonist MRS2179 (1 muM) and P2Y12 receptor antagonist cangrelor (AR-C69931MX; 0.1 muM) inhibited EKA/B-mediated aggregation by 90.5% (+/- 4.8%; Figure 2C) and 99.4% (+/- 0.6%; Figure 2D), respectively.
###end p 40
###begin p 41
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EKA/B-mediated platelet aggregation is dependent on ADP and TXA<sub>2</sub> release.</bold>
###xml 182 183 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 950 951 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 962 963 943 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
EKA/B-mediated platelet aggregation is dependent on ADP and TXA2 release. Platelets were stimulated with EKA/B (5 muM) in the presence of indomethacin (10 muM) or vehicle control (Me2SO, A), SQ294890 or vehicle control (Tyrode-HEPES buffer, B), cangrelor (AR-C69931MX) or vehicle control (Tyrode-HEPES buffer, C), or MRS2179 or vehicle control (Tyrode-HEPES buffer, D), and aggregation was measured under constant stirring conditions at 37degreesC. Washed platelets were stimulated with subaggregatory concentrations of EKA/B (1.25 muM) alone, thrombin (Thr.; 0.005 U/mL), collagen (Coll.; 0.5 mug/mL), adrenaline (Adr.; 10 muM), or 5-HT (10 muM) in combination with EKA/B (1.25muM) or vehicle control (acetic acid 0.001%), and aggregation was measured at 37degreesC under constant stirring conditions (E). Individual aggregation traces are representative of 3 separate experiments (A,E). Numerical data represent means plus or minus SEM. (n = 3); **P < .01; ***P < .001.
###end p 41
###begin p 42
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 196 201 196 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref></sup>
###xml 599 607 594 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
EKA/B and SP therefore display typical characteristics of weak platelet agonists whose functional effects are dependent on secretion and synthesis of secondary mediators to elicit a full response.26,27 Consistent with this, EKA/B was found to synergise with a number of other agonists. Platelets stimulated with 1.25 muM EKA/B, 0.005 U/mL thrombin, 0.5 mug/mL collagen, 10 muM adrenaline, or 10 muM 5-HT displayed little or no evidence of aggregation. Combining each of the agonists with 1.25 muM EKA/B resulted in strong platelet aggregation, confirming that EKA/B can evoke synergistic responses (Figure 2E).
###end p 42
###begin title 43
Peripheral tachykinins signal through the NK1 receptor on platelets
###end title 43
###begin p 44
###xml 421 429 411 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 643 651 623 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
To establish whether the effects of EKA/B and SP on platelets are mediated by the NK1 receptor, aggregation assays were carried out in the presence of the NK1 antagonist L733060. Platelet aggregation stimulated by EKA/B (5 muM) was inhibited by 8.7% (+/- 3.2%), 22.2% (+/- 7.1%), 65.3% (+/- 14.5%), and 99.6% (+/- 0.4%) at concentrations of 5, 10, 20, and 30 muM L733030, respectively, compared with the vehicle control (Figure 3A). Similarly, SP (5 muM)-mediated platelet aggregation was inhibited by 17.6% (+/- 2.9%), 21.9% (+/- 1.0%), 70.2% (+/- 8.7%), and 85.3% (+/- 0.5%) by 5, 10, 20, and 30 muM concentrations of L733030, respectively (Figure 3B).
###end p 44
###begin p 45
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Peripheral tachykinins signal through the NK1 receptor on platelets.</bold>
###xml 334 335 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 345 346 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 357 358 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Peripheral tachykinins signal through the NK1 receptor on platelets. Washed platelets were stimulated with EKA/B (5 muM) (A) or SP (5 muM) (B) in the presence of NK1 antagonist L733060 or vehicle control (Tyrode-HEPES buffer), and aggregation was measured using optical aggregometry. Data represent means plus or minus SEM. (n = 3); *P < .05; **P < .01; ***P < .001.
###end p 45
###begin title 46
Platelet NK1 receptor signaling
###end title 46
###begin p 47
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 79 80 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 102 107 102 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref></sup>
###xml 121 122 121 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</sub>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 288 289 288 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 310 315 310 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>
###xml 556 564 546 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 711 712 701 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 771 772 761 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 836 844 826 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 947 948 937 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 1202 1210 1183 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1266 1267 1247 1248 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 1406 1407 1387 1388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 1486 1494 1467 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1559 1560 1540 1541 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 1614 1622 1595 1603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1792 1793 1773 1774 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2099 2107 2070 2078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 2219 2220 2189 2190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 620 625 <span type="species:ncbi:10090">mouse</span>
###xml 2231 2235 <span type="species:ncbi:10090">mice</span>
The NK1 receptor has been demonstrated in cell lines to couple to both Gq and Gs classes of G protein.28,29 Coupling to Gs would result in reduced platelet activity, and therefore we investigated the role of Gq in tachykinin-mediated platelet activation using the recently characterized Gq inhibitor YM-254890.30,31 Platelet aggregation evoked by EKA/B (5 muM) was inhibited in a dose-dependent manner by YM-254890 by 16.3% (+/- 5.9%), 54.8% (+/- 3%), 99.0% (+/- 0.3%), and 99.3% (+/- 0.7%) at concentrations of 0.01, 0.05, 0.1, and 0.5 muM, respectively (Figure 4A). Similarly, platelet aggregation stimulated by SP in mouse platelets, assessed by single-cell counts, was abolished in platelets obtained from Gq-deficient litter mates, confirming the importance of the Gq signaling pathway in tachykinin-mediated platelet aggregation (Figure 4B). This was further illustrated by the inhibition of phospholipase C (PLC), which lies downstream of Gq. The PLC inhibitor U73122 reduced EKA/B-mediated aggregation by 13.5% (+/- 5.6%), 27.5% (+/- 12.5%), 50.2% (+/- 20.7%), and 70.75% (+/- 7.9%) at concentrations of 0.5, 1.0, 2.5, and 5 muM, respectively, whereas the inactive analog U73343 had no effect (Figure 4C). Although these data confirm the involvement of the Gq/PLC signaling pathway in platelet aggregation stimulated by NK1 agonists, they do not demonstrate direct coupling of the NK1 receptor to Gq since EKA/B-mediated aggregation is dependent on released secondary agonists (Figure 2A-D). To determine whether the NK1 receptor couples directly to Gq or whether the inhibition of aggregation observed in Figure 4A-C was solely through inhibition of secondary agonists, NK1-mediated arachidonic acid mobilization was measured in the presence of YM-254890, as this occurs prior to TXA2 release and granule secretion (Figure S2). YM254890 inhibited arachidonic acid liberation stimulated by 10 muM EKA/B dose-dependently by 26.6% (+/- 13.6%), 46.9% (+/- 4.2%), 73% (+/- 2%), and 79.1% (+/- 9.5%), at concentrations of 0.001, 0.01, 0.1, and 1 muM, respectively, compared with vehicle control (Figure 4D). Moreover, increased arachidonic acid release stimulated by 10 muM SP was abolished in platelets taken from Gq-deficient mice (data not shown).
###end p 47
###begin p 48
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Platelet NK1 receptors couple to G<sub>q</sub> G proteins.</bold>
###xml 103 104 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 206 207 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 323 324 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 687 688 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 805 806 795 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 816 817 806 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 828 829 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 168 173 <span type="species:ncbi:10090">mouse</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 507 512 <span type="species:ncbi:10090">mouse</span>
Platelet NK1 receptors couple to Gq G proteins. Washed human platelets (A,C) or platelets loaded with [3H] arachidonic acid (D) were stimulated with EKA/B (5 muM), and mouse platelets were taken from Galphaq-deficient mice or their litter-match controls and stimulated with SP (10 muM, B), and in the presence of the Galphaq inhibitor YM-254890 (A,D) or PLC inhibitor U73122 or its inactive analog U73343 (C). The results represent platelet aggregation as a percent of the respective vehicle control (A,C), mouse platelet aggregation assessed by single-cell number is displayed as a percentage of basal cell number (B), and arachidonic acid release presented as the percentage of total [3H] arachidonic acid taken up into the platelet minus basal release (D). All data represent means plus or minus SEM. *P < .05; **P < .01; ***P < .001; n = 3 (A,C,D) or 6 (B).
###end p 48
###begin title 49
###xml 37 42 <span type="species:ncbi:9606">human</span>
EKA/B immunoreactivity is present in human platelets
###end title 49
###begin p 50
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 724 725 724 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 880 888 880 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1309 1313 1304 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 578 583 <span type="species:ncbi:9606">Human</span>
###xml 1303 1308 <span type="species:ncbi:9606">human</span>
We have reported that platelets contain SP that is secreted during activation, and have proposed this to contribute to positive feedback regulation of platelet function. Given the presence of TAC4 mRNA in megakaryocytic cells, it is possible that platelets also contain endokinins, although cross-reactivity between available immunoassays for SP and EKA/B, due to sequence identity at the C-terminus, prevented confirmation of this. Antibodies were therefore raised against a peptide sequence that lies upstream of the common decapeptide (EKA/B) that is present in EKA and EKB. Human platelets were allowed to adhere to glass coverslips and probed using endokinin-selective antisera. Platelets were also prelabeled with DIOC6 and analyzed by confocal microscopy to detect platelets (488 nm) and endokinin (594 nm). Platelets stained positively for the presence of the endokinins (Figure 5). Antibody binding was not detected using preimmune serum or with antiendokinin antiserum preincubated with an excess of immunogen peptide. Similar results were obtained in the presence of saturating concentrations of mAb IV.3 (1 mug/mL) to block potential antibody binding of the platelet IgG receptor FcgammaRIIa (not shown). This is the first confirmation that endokinins are translated in tissues and that the human TAC4 gene is functional.
###end p 50
###begin p 51
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EKA/B immunoreactivity is present in human platelets.</bold>
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 54 59 <span type="species:ncbi:9606">Human</span>
EKA/B immunoreactivity is present in human platelets. Human platelets were labeled with the lipophilic fluorescent dye DIOC6, applied to glass coverslips, and fixed. Platelets were visualized by DIC microscopy and confocal microscopy at 488 nm. Endokinin expression in platelets was detected at 594 nm using an antiendokinin antibody and Texas red-conjugated secondary antibody. Parallel control experiments were performed using preimmune antiserum, and antiendokinin antiserum to which immunogen antibody had been previously added (peptide-adsorbed antiendokinin). Confocal fluorescence microscopic data represent composite images. Data are representative of 4 separate experiments.
###end p 51
###begin title 52
NK1 is required for thrombus formation under arterial flow conditions
###end title 52
###begin p 53
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 474 482 470 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 720 728 716 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 855 863 849 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1091 1093 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1091 1093 1085 1087 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B32">32</xref></sup>
###xml 1193 1195 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1193 1195 1187 1189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B33">33</xref></sup>
###xml 1310 1318 1302 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1515 1523 1505 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 1188 1192 <span type="species:ncbi:10090">mice</span>
###xml 1213 1217 <span type="species:ncbi:10090">mice</span>
###xml 1407 1412 <span type="species:ncbi:10090">mouse</span>
###xml 1502 1507 <span type="species:ncbi:10090">mouse</span>
###xml 1591 1596 <span type="species:ncbi:9606">human</span>
To establish whether NK1 agonists are involved in thrombus formation, human whole blood was perfused through collagen-coated microcapillary tubes at a shear (laminar flow) rate of 1000 s-1 in the presence of NK1 antagonist L733060 (10 muM) or vehicle control, and thrombus formation was measured. Thrombus volume, calculated as the mean of 5 randomly selected fields of view, was reduced by 57.2% (+/- 16.0%) in the presence of 10 muM L733060 compared with vehicle control (Figure 6A,B). To measure thrombus formation along the whole capillary, lysis buffer was passed through each capillary and protein concentration of the lysates measured as an indication of platelet number. Consistent with the thrombi volume data (Figure 6B), L733060 reduced protein concentration by 65.1% (+/- 2.7%) compared with thrombi formed in the presence of vehicle control (Figure 6C). The concentration of L733060 used was relatively high compared with Ki values derived from binding studies, although similar concentrations have been used to inhibit functional responses to SP in other peripheral cell types.32 To address this concern, thrombus formation was examined in blood from NK1 receptor-deficient mice.33 Blood from these mice produced thrombi 76% (+/- 7.8%) smaller than that formed from litter matched control blood (Figure 6D,E). Similarly, the protein concentration of thrombi formed from NK1 receptor-deficient mouse blood was 79.7% (+/- 5.5%) lower than that of thrombi formed from litter-matched control mouse blood (Figure 6F), indicating an important role for NK1 and substantiating data on human platelets using L733060.
###end p 53
###begin p 54
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tachykinins and their receptor are important for normal thrombus formation.</bold>
###xml 248 252 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC1</italic>
###xml 365 367 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 633 634 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 644 645 643 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 656 657 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
Tachykinins and their receptor are important for normal thrombus formation. Whole blood from drug-free donors (A-C) in the presence of NK1 antagonist, L733060 (10 muM), or blood obtained from NK1-deficient mice or litter-matched controls (D-F), or TAC1-deficient mice or control mice (G-I), was perfused through collagen coated capillaries at a sheer rate of 1000 s-1. Pictures of the thrombi were taken using confocal microscopy (A,D,G), the volume of the thrombi quantified (B,E,H), and protein concentration of the thrombi measured (C,F,I). Numeric data represent means plus or minus SEM. n = 3 (B,C), 8 (E), 6 (F), and 9 (H,I). *P < .05; **P < .01; ***P < .001.
###end p 54
###begin p 55
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 103 105 103 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B18">18</xref></sup>
###xml 280 288 278 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 390 394 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC1</italic>
###xml 444 452 440 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 485 489 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC1</italic>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
To examine the involvement of SP in thrombus formation, blood obtained from mice lacking the TAC1 gene,18 which codes for SP, was perfused through collagen-coated microcapillaries, and thrombi formation was measured. Thrombi volume was 44% +/- 9.5% smaller than in control blood (Figure 6G,H). A reduction of 80.9% (+/- 7.8%) in protein concentration was observed in lysates collected from TAC1-deficient thrombi compared with control thrombi (Figure 6I). NKA, which is also absent in TAC1-deficient mice, has no effect on platelets (G. J. Graham and J.M.G., unpublished data, 2002), suggesting the effects observed were a result of SP deficiency.
###end p 55
###begin title 56
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Increased bleeding and diminished thrombosis are observed in mice in the absence of NK1 receptor function
###end title 56
###begin p 57
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 269 271 269 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B33">33</xref></sup>
###xml 312 320 312 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 467 468 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 171 176 <span type="species:ncbi:10090">mouse</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
Having established a role for peripheral tachykinins in thrombus formation in vitro, experiments were performed to examine the significance of this for hemostasis using a mouse tail-bleeding assay. Bleeding time was found to be extended moderately in NK1-deficient mice33 in comparison with littermate controls (Figure 7A). The mean maximum duration for bleeding extended from 5.54 (+/- 0.51) minutes in control mice to 7.90 (+/- 0.71) minutes in NK1-deficient mice (P = .01; n = 10), with 2 NK1 mice bleeding beyond the 10-minute maximum duration of the assay. These experiments confirmed a role for tachykinin signaling in normal hemostasis.
###end p 57
###begin p 58
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Increased bleeding and diminished thrombosis are observed in mice in the absence of NK1 receptor function.</bold>
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 447 450 447 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">111</sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
###xml 571 575 <span type="species:ncbi:10090">Mice</span>
###xml 947 951 <span type="species:ncbi:10090">mice</span>
Increased bleeding and diminished thrombosis are observed in mice in the absence of NK1 receptor function. The time to cessation of bleeding following transection of the tail tip of NK1 receptor-deficient mice and littermate controls was measured. The assay was terminated after 10 minutes. Data represent individual mice (n = 10) with mean value indicated. **P < .01 (A). Collagen-induced thromboembolism was measured in Balb/c mice infused with 111Indium oxine-labeled platelets by measurement of the accumulation of radiolabeled platelets in the pulmonary region (B). Mice were treated with the NK1 receptor antagonist L733060 (10 mg/kg) or vehicle alone prior to stimulation of thromboembolism through intravenous administration of collagen (100 mug/kg). Data were acquired as percentage change in basal counts and expressed as maximal percentage response (embolic response, mean +/- SEM) where measurements acquired for vehicle alone treated mice were taken as 100%.
###end p 58
###begin p 59
###xml 567 575 564 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 251 255 <span type="species:ncbi:10090">Mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
To assess the potential impact of tachykinin and NK1 receptor signaling in thrombosis, experiments were performed to establish whether administration of the NK1 receptor antagonist L733060 provides protection against collagen-induced thromboembolism. Mice were injected with vehicle control or L733060, 5 minutes prior to administration of collagen (100 mug/kg), and platelet accumulation in the pulmonary vasculature measured. Results demonstrated a 30% (+/- 4.7%) reduction in maximal platelet accumulation in mice treated with L733060 compared with vehicle alone (Figure 7B). When performing these experiments, it was also noted that mice treated with the NK1 receptor antagonist experienced prolonged bleeding from the femoral vein after the collagen injection. These data further support the notion that tachykinins released from platelets play a role as secondary platelet agonists that are important for platelet recruitment to a growing thrombus through stimulation of the NK1 receptor.
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 449 451 449 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 291 296 <span type="species:ncbi:9606">human</span>
We have reported previously the presence of SP immunoreactivity in platelets, its secretion during activation, and its ability to stimulate platelet activation. We have therefore proposed SP to be a positive feedback regulator of platelet activation. The recently identified products of the human TAC4 gene, EKA/B share sequence identity with SP at C-termini, preferentially activate the NK1 receptor, and cross-react with available SP immunoassays.10 These data, together with the detection of TAC4 mRNA in megakaryocytic cells, indicate that EKA/B may also be present in platelets and contribute to tachykinin-mediated regulation of platelet function.
###end p 61
###begin p 62
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 15 17 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 230 231 230 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 414 415 414 415 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 421 422 421 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 454 456 454 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B34">34</xref></sup>
###xml 481 482 481 482 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 490 492 490 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 509 510 509 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 516 517 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 750 752 750 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
EKA/B, like SP,10 stimulated calcium-dependent platelet aggregation and alpha- and dense-granule secretion. It was also able to liberate arachidonic acid from platelet membranes, promoting the synthesis of the platelet agonist TXA2. Typical of other weak platelet agonists, EKA/B was capable of synergism with other agonists. It has been demonstrated that for platelet aggregation to occur, costimulation of both Gi and Gq signaling pathways is required.34 Purinergic receptors P2Y1 and P2Y12 are coupled to Gq and Gi signaling pathways, respectively. Inhibition of either of these abolishes aggregation, which can be recovered by stimulation of an alternative receptor coupled to the inhibited pathway. The range of agonists with which EKA/B (and SP10) synergize are coupled to a variety of signaling pathways. It is therefore likely that the synergy achieved by costimulation with this peptide was in part through the effects of secondary agonists. This correlates with the significant increase in dense granule secretion upon stimulation with 1.25 muM EKA/B observed in this study.
###end p 62
###begin p 63
###xml 439 440 439 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
The involvement of NK1 receptors on platelets on the responses of these cells to SP and EKA/B was confirmed through the use of a selective NK1 receptor antagonist that was able to reduce substantially platelet aggregation. Signaling downstream of the NK1 receptor is potentially complex with possible contributions from a range of G proteins. Experiments carried out in this study illustrate that in platelets the NK1 receptor couples to Gq.
###end p 63
###begin p 64
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
This study confirms the ability of NK1 receptor agonists SP and EKA/B to regulate platelet function. Furthermore, NK1 receptor-blocking antibodies inhibit platelet responses to collagen,10 indicating that NK1 agonists are released from activated platelets and act as paracrine agonists.
###end p 64
###begin p 65
###xml 407 411 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 585 589 585 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 798 802 798 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 579 584 <span type="species:ncbi:9606">human</span>
###xml 904 910 <span type="species:ncbi:9606">humans</span>
Due to the inability of existing antibodies or assays to distinguish between SP and EKA/B, it was initially unclear whether platelets secrete SP, EKA and EKB, or each of these. Antibodies were therefore raised to a peptide sequence that is present in endokinins A and B that lies upstream of the decapeptide that was used to stimulate platelet function and is therefore not shared with SP, and is unique to TAC4 gene products. Immunofluorescence experiments demonatrated the presence of TAC4-derived peptides in these cells. These are the first experiments that confirm that the human TAC4 gene is functional and that its products are translated in peripheral tissues. Furthermore, this indicates a potential role, along with SP, in the regulation of hemostasis. It is interesting to note that the TAC4 gene is not well conserved across species, which is suggestive that this gene is evolving rapidly in humans and perhaps is selected for platelet activation.
###end p 65
###begin p 66
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 262 264 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B33">33</xref></sup>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
The importance of the peripheral tachykinins for thrombus formation was demonstrated on immobilized collagen under arterial flow conditions, which was reduced in the presence of NK1 receptor antagonist L733060. Moreover, whole blood taken from NK1-deficient mice33 produced markedly smaller thrombi compared with blood from control mice. These data illustrate a role for the NK1 receptor in thrombus formation and suggest that NK1 agonists are present in platelets and released upon activation, and at sufficiently high concentrations, act as positive feedback regulators.
###end p 66
###begin p 67
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
Blood obtained from TAC1-deficient mice produced significantly smaller thrombi than blood obtained from litter-matched control mice. This reduction was comparable with that seen in blood obtained from NK1 receptor-deficient mice, suggesting that physiologically, SP is a major NK1 agonist responsible for amplifying the platelet response through the NK1 receptor. The relatively high concentrations of NK1 receptor agonists required to stimulate platelet signaling indicate that concentrations in the vicinity of a developing thrombus are likely to be similarly high, although our data suggest that synergism with other agonists is also critical. Given the presence of EKA/B in platelets, it is likely that they also contribute to thrombus formation through the stimulation of NK1 signaling, although the future development of endokinin-specific immunoassays will be necessary to measure the levels secreted from platelets.
###end p 67
###begin p 68
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 197 199 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B33">33</xref></sup>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC1</italic>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 364 366 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B18">18</xref></sup>
###xml 547 551 547 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAC4</italic>
###xml 250 254 <span type="species:ncbi:10090">mice</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 590 596 <span type="species:ncbi:9606">humans</span>
To examine the contribution of peripheral tachykinins and NK1 receptor signaling to hemostasis, tail bleeding assays were performed. Bleeding was prolonged moderately in NK1 receptor-deficient mice33 in comparison with littermate controls, with some mice bleeding beyond the 10-minute duration of the assay. Similar assays were performed using TAC1-deficient mice,18 where no difference was observed in comparison with controls (data not shown). This is interesting, since it is indicative of redundancy, highlighting the potential involvement of TAC4 gene products (HK-1 in mice, EKA/B in humans).
###end p 68
###begin p 69
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
Since these data implicate tachykinin signaling in the control of hemostasis, we have begun to assess contribution of the NK1 receptor to thrombosis using a thromboembolic model in mice. The administration of an NK1 receptor antagonist to mice resulted in a 30% reduction in the embolic response compared with infusion of vehicle alone. While it will be important in the future to examine the role of the NK1 receptor and the peripheral tachykinins in thrombosis using additional experimental models in vivo, the results of this study indicate that the inhibition of the actions of tachykinins may provide a new therapeutic approach for the prevention of thrombosis.
###end p 69
###begin title 70
Supplementary Material
###end title 70
###begin title 71
[Supplemental Figures]
###end title 71
###begin p 72
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Blood</italic>
An Inside Blood analysis of this article appears at the front of this issue.
###end p 72
###begin p 73
The online version of this article contains a data supplement.
###end p 73
###begin p 74
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
###end p 74
###begin title 75
Acknowledgments
###end title 75
###begin p 76
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 250 252 250 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 128 143 <span type="species:ncbi:10090">transgenic mice</span>
The authors would like to thank Francois Lanza (Strasbourg, France) and Stefan Offermans (Heidelberg, Germany) for Gq-deficient transgenic mice, Astellas (Tokyo, Japan) for Gq inhibitor YM254890, and The Medicines Company (Parsippany, NJ) for the P2Y12 antagonist cangrelor. We are also grateful to Hayley Mylroie for assistance with immunofluorescence experiments.
###end p 76
###begin p 77
This work was supported by research grants from the British Heart Foundation and Wellcome Trust and National Centre for the Replacement, Refinement and Reduction of Animals in Research.
###end p 77
###begin title 78
Authorship
###end title 78
###begin p 79
Contribution: S.J. designed and performed research, analyzed and interpreted data, and drafted the manuscript; K.L.T., T.S., W.J.K., and N.E.B. performed research and analyzed and interpreted data; P.J.L. analyzed and interpreted data and drafted the manuscript; A.Z. and S.P.H. contributed vital analytical tools and drafted the manuscript; M.E. designed research and interpreted data; and J.M.G. designed and performed research, analyzed and interpreted data, and drafted the manuscript.
###end p 79
###begin p 80
Conflict-of-interest disclosure: The authors declare no competing financial interests.
###end p 80
###begin p 81
###xml 157 182 157 182 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j.m.gibbins@reading.ac.uk</email>
Correspondence: Jonathan M. Gibbins, School of Biological Sciences, University of Reading, Whiteknights, Reading, Berkshire RG6 6AJ, United Kingdom; e-mail: j.m.gibbins@reading.ac.uk.
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
Mechanisms initiating platelet thrombus formation.
###end article-title 83
###begin article-title 84
Adhesion receptor signalling and the regulation of thrombus formation.
###end article-title 84
###begin article-title 85
Integrin signaling: the platelet paradigm.
###end article-title 85
###begin article-title 86
Signaling receptors on platelets and megakaryocyte.
###end article-title 86
###begin article-title 87
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.
###end article-title 87
###begin article-title 88
CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism.
###end article-title 88
###begin article-title 89
Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A.
###end article-title 89
###begin article-title 90
Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury.
###end article-title 90
###begin article-title 91
Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred.
###end article-title 91
###begin article-title 92
Tachykinins regulate the function of platelets.
###end article-title 92
###begin article-title 93
###xml 36 41 <span type="species:ncbi:9606">human</span>
Characterization of the endokinins: human tachykinins with cardiovascular activity.
###end article-title 93
###begin article-title 94
Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia.
###end article-title 94
###begin article-title 95
Hematopoietic modulation by the tachykinins.
###end article-title 95
###begin article-title 96
The tachykinin peptide family.
###end article-title 96
###begin article-title 97
Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis.
###end article-title 97
###begin article-title 98
Identification, localization and receptor characterization of novel mammalian substance P-like peptides.
###end article-title 98
###begin article-title 99
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Altered nociception, analgesia and aggression in mice lacking the receptor for substance P.
###end article-title 99
###begin article-title 100
###xml 15 19 <span type="species:ncbi:10090">mice</span>
Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene.
###end article-title 100
###begin article-title 101
A role for the thiol isomerase ERP5 in platelet function.
###end article-title 101
###begin article-title 102
A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase C gamma2 in platelets independent of the integrin alpha2beta1.
###end article-title 102
###begin article-title 103
Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets.
###end article-title 103
###begin article-title 104
###xml 83 88 <span type="species:ncbi:9606">human</span>
Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets.
###end article-title 104
###begin article-title 105
###xml 62 67 <span type="species:ncbi:9606">human</span>
Localization of cyclo-oxygenase and thromboxane synthetase in human-platelet intracellular membranes.
###end article-title 105
###begin article-title 106
###xml 25 26 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 82 87 <span type="species:ncbi:9606">human</span>
Cytosolic phospholipase A2 is phosphorylated in collagen- and thrombin-stimulated human platelets independent of protin kinase C and mitogen-activated protein kinase.
###end article-title 106
###begin article-title 107
The eicosanoids and their biochemical-mechanisms of action.
###end article-title 107
###begin article-title 108
The role of heterotrimeric G proteins in platelet activation.
###end article-title 108
###begin article-title 109
###xml 143 148 <span type="species:ncbi:9606">human</span>
Involvement of thromboxane A2 and tyrosine kinase in the synergistic interaction of platelet activating factor and calcium ionophore A23187 in human platelet aggregation.
###end article-title 109
###begin article-title 110
Tachykinins: Receptor to effector.
###end article-title 110
###begin article-title 111
Tachykinin receptors and tachykinin receptor antagonists.
###end article-title 111
###begin article-title 112
A novel G alpha(q/11)-selective inhibitor.
###end article-title 112
###begin article-title 113
###xml 62 80 <span type="species:ncbi:306190">Chromobacterium sp</span>
YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp QS3666.
###end article-title 113
###begin article-title 114
L-733,060, a novel tachykinin NK1 receptor antagonist; Effects in [Ca2+](i) mobilisation, cardiovascular and dural extravasation assays.
###end article-title 114
###begin article-title 115
Neurogenic amplification of immune complex inflammation.
###end article-title 115
###begin article-title 116
Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.
###end article-title 116

